Sign in
Taking peopleNo phase

Blood markers to spot hidden cancer in people with venous thromboembolism

Studies blood markers of inflammation to find hidden cancer in people with blood clots.

Key facts

Who runs it
Danderyd Hospital
Where
Sweden2 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
Identification of Novel Biomarkers to Aid in the Detection of Occult Cancer in Patients With Venous Thromboembolism
Status
Recruiting
People taking part
1,000 people, planned
Started
1 Mar 2017
Expected to end
31 Dec 2028
Type of study
Observational
Record updated
20 December 2018

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a new blood clot in a deep vein or in the lungs (venous thromboembolism). It studies blood markers that may help find hidden cancer.

Age
18 years or older
Sex
All sexes
Disease stage
A blood clot in the deep veins of the arms, legs or pelvis (iliac veins), and/or in the lungs. It must be found by ultrasound, phlebography, CT scan or angiography.

Main reasons for not taking part

  • More than 2 days have passed since the blood clot was diagnosed
  • No blood sample taken at the start of the study

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Venous thromboembolism (thrombosis in the deep venous system of upper or lower extremities or iliac veins and/or pulmonary embolism) as detected by ultrasonography, phlebography, computer tomography, or angiography
  • > 18 years or older
  • Written informed consent

Who cannot take part

  • > 2 days after VTE diagnosis
  • No blood withdrawal at baseline

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Venous thromboembolism is a common and serious complication in cancer, and is associated with a substantially increased morbidity and mortality. Furthermore, VTE may be the earliest sign of cancer. Recent studies, however, fail to show a clinical benefit of extended cancer screening in this patient population. Better risk prediction models are therefore warranted to identify VTE patients who would benefit from a rapid and extensive cancer screening. Inflammation and hypercoagulability are considered hallmarks of cancer, and emerging light is being shed on the potential of various markers of inflammation and coagulation in cancer diagnostics and prognostics. Among the inflammatory and thrombotic processes linked to cancer is the neutrophil release of web-like nuclear chromatin (DNA and histones), referred to as neutrophil extracellular traps (NETs). Driven by the tumor environment, NETs have recently been shown to play a central role in tumor progression, metastasis, and tumor-associated thrombosis.

Read full original descriptionShow less

The investigators hypothesize that an enhanced inflammatory state may be predictive of an underlying cancer in patients presenting with VTE. The present study is an ongoing prospective study with the primary aim to investigate the diagnostic potential of markers of inflammation, including markers of NETs, in detecting occult cancer in patients presenting with VTE. Secondary aims are to include other biomarkers of cancer, and to assess whether any or a combination of these biomarkers may be prognostic of occult cancer, recurrent thrombotic events, mortality, or cancer disease progression in VTE patients with an underlying malignancy.

The group in the trial

  • Venous thromboembolism

    Patients presenting with venous thromboembolism (thrombosis in the deep venous system of upper or lower extremities or iliac veins and/or pulmonary embolism) as detected by ultrasonography, phlebography, computer tomography, or angiography

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Identification of Novel Biomarkers to Aid in the Detection of Occult Cancer in Patients With Venous Thromboembolism
Plain-language title
Blood markers to spot hidden cancer in people with venous thromboembolismGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
20 December 2018